1
|
Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R. Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project. Br J Haematol 2024. [PMID: 38532575 DOI: 10.1111/bjh.19433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 02/27/2024] [Accepted: 03/16/2024] [Indexed: 03/28/2024]
Abstract
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
Collapse
Affiliation(s)
- M Civallero
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - J G Schroers-Martin
- Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA
| | - S Horwitz
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| | - M Manni
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Y Stepanishyna
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
| | - M E Cabrera
- Sección Hematología, Hospital del Salvador, Universidad de Chile, Santiago, Chile
| | - J Vose
- Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - M Spina
- Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
| | - F Hitz
- Department of Oncology/Haematology, The Swiss Group for Clinical Cancer Research, Cantonal Hospital, St Gallen, Switzerland
| | - A Nagler
- Department of Bone Marrow Transplantation, Tel-Aviv University, Tel-Aviv, Israel
| | - S Montoto
- Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - C Chiattone
- Higienopolis and Santa Casa Medical School of Sao Paulo, Samaritano Hospital, São Paulo, Brazil
| | - T Skrypets
- Hematology and Cell Therapy Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - M A Perez Saenz
- Department of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
| | - G Priolo
- Hematology 2, San Giovanni Battista Hospital and University, Turin, Italy
| | - S Luminari
- Hematology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - A Lymboussaki
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - A Pavlovsky
- Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina
| | - D Marino
- Department of Oncology, Oncology 1 Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - M Liberati
- A.O. Santa Maria, S.C. di Oncoematologia di Terni, Università Degli Studi di Perugia, Perugia, Italy
| | - J Trotman
- Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia
| | - D Mannina
- Hematology Unit, AO Papardo, Messina, Italy
| | - M Federico
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - R Advani
- Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA
| |
Collapse
|
2
|
Kahn J, Dabaja B, Wu S, Kelly K, Berkahn L, Pavlovsky A, Sureda A, LaCasce A. Classic Hodgkin lymphoma. Hematol Oncol 2023. [PMID: 38037872 DOI: 10.1002/hon.3239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Revised: 10/24/2023] [Accepted: 10/30/2023] [Indexed: 12/02/2023]
Abstract
Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15-39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5-year overall survival (OS) approaching 90% today. [1](#ref-0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long-term outcomes. Despite continued improvements in up-front and salvage therapy, long-term survivors of HL experience several treatment-associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high-priority in the field.
Collapse
Affiliation(s)
- Justine Kahn
- Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, USA
| | - Bouthaina Dabaja
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Susan Wu
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Kara Kelly
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
| | - Leanne Berkahn
- Leukaemia and Blood Cancer New Zealand, Auckland, New Zealand
| | | | - Anna Sureda
- Institut Catala D'Oncologia Badalona, Badalona, Spain
| | - Ann LaCasce
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Linton KM, Specht L, Pavlovsky A, Thompson CA, Kimby E, de Jong D, Nastoupil LJ, Cottereau AS, Casulo C, Sarkozy C, Okosun J. Personalised therapy in follicular lymphoma - is the dial turning? Hematol Oncol 2023. [PMID: 37482955 DOI: 10.1002/hon.3205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 05/25/2023] [Accepted: 06/17/2023] [Indexed: 07/25/2023]
Abstract
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.
Collapse
Affiliation(s)
- Kim M Linton
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
- Division of Cancer Sciences, The Manchester Cancer Research Centre, University of Manchester, Manchester, UK
| | - Lena Specht
- Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Astrid Pavlovsky
- Department of Hematology, Fundaleu Clinical Research Center, Buenos Aires, Argentina
- Centro de Helmatología Pavlovsky, Medical Director, Buenos Aires, Argentina
| | - Carrie A Thompson
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
| | - Eva Kimby
- Department of Medicine Karolinska Institutet, Center of Hematology, Stockholm, Sweden
| | - Daphne de Jong
- Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Loretta J Nastoupil
- Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Anne-Ségolène Cottereau
- Department of Nuclear Medicine, Cochin Hospital, APHP, University of Paris Cité, Paris, France
| | - Carla Casulo
- Department of Medicine, University of Rochester, Rochester, New York, USA
| | | | - Jessica Okosun
- Centre for Haemato-Oncology Barts Cancer Institute, Queen Mary University of London, London, UK
| |
Collapse
|
4
|
Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229-1253. [PMID: 35653592 PMCID: PMC9479027 DOI: 10.1182/blood.2022015851] [Citation(s) in RCA: 457] [Impact Index Per Article: 228.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 05/18/2022] [Indexed: 11/20/2022] Open
Abstract
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Collapse
Affiliation(s)
- Elias Campo
- Haematopathology Section, Hospital Clínic of Barcelona, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain
| | - Elaine S Jaffe
- Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - James R Cook
- Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
| | - Leticia Quintanilla-Martinez
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
| | - Steven H Swerdlow
- Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA
| | | | - Pierre Brousset
- Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Lorenzo Cerroni
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - Laurence de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland
| | - Stefan Dirnhofer
- Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Ahmet Dogan
- Laboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Andrew L Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| | - Falko Fend
- Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany
| | | | - Philippe Gaulard
- Department of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
- Mondor Institute for Biomedical Research, INSERM U955, Faculty of Medicine, University of Paris-Est Créteil, Créteil, France
| | - Paolo Ghia
- Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy
| | - Steven M Horwitz
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Rebecca L King
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| | - Gilles Salles
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Jesus San-Miguel
- Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain
| | - John F Seymour
- Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
| | | | - Julie M Vose
- Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE
| | - Emanuele Zucca
- Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Ranjana Advani
- Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA
| | - Stephen Ansell
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
| | - Wing-Yan Au
- Blood-Med Clinic, Hong Kong, People's Republic of China
| | - Carlos Barrionuevo
- Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
| | - Leif Bergsagel
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ
| | - Wing C Chan
- Department of Pathology, City of Hope National Medical Center, Duarte, CA
| | - Jeffrey I Cohen
- Medical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD
| | - Francesco d'Amore
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
| | - Andrew Davies
- Cancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom
| | - Brunangelo Falini
- Institute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy
| | - Irene M Ghobrial
- Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Harvard University, Boston, MA
| | - John R Goodlad
- National Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom
| | - John G Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Eric D Hsi
- Department of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC
| | - Brad S Kahl
- Oncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO
| | - Won-Seog Kim
- Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Shaji Kumar
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
| | | | - Camille Laurent
- Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France
| | - Georg Lenz
- Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
| | - John P Leonard
- Weill Department of Medicine, Weill Medical College, Cornell University, New York, NY
| | - Michael P Link
- Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA
| | - Armando Lopez-Guillermo
- Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Maria Victoria Mateos
- Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain
| | - Elizabeth Macintyre
- Laboratoire d'Onco-Hématologie, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris Cité and Institut Necker-Enfants Malades, Paris, France
| | - Ari M Melnick
- Division of Hematology and Oncology, Weill Medical College, Cornell University, New York, NY
| | - Franck Morschhauser
- Department of Hematology, Centre Hospitalier Universitaire de Lille, University Lille, Lille, France
| | - Shigeo Nakamura
- Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan
| | - Marina Narbaitz
- Department of Pathology, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina and Fundacion para combatir la leucemia (FUNDALEU), Buenos Aires, Argentina
| | - Astrid Pavlovsky
- Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina
| | - Stefano A Pileri
- Haematopathology Division, IRCCS, Istituto Europeo di Oncologia, Milan, Italy
| | - Miguel Piris
- Jiménez Díaz Foundation University Hospital, Universidad Autónoma de Madrid, Madrid, Spain
| | - Barbara Pro
- Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
| | - Vincent Rajkumar
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| | - Steven T Rosen
- Beckman Research Institute, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
| | - Birgitta Sander
- Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Laurie Sehn
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
| | | | - Sonali M Smith
- Section of Hematology/Oncology, University of Chicago, Chicago, IL
| | - Louis M Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Catherine Thieblemont
- Service Hémato-Oncologie, AP-HP, Hôpital Saint-Louis, Paris, France
- DMU-DHI, Université de Paris-Paris Diderot, Paris, France
| | - Thomas Tousseyn
- Department of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium
| | - Wyndham H Wilson
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
| | - Tadashi Yoshino
- Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan
| | - Pier-Luigi Zinzani
- Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
| | - Martin Dreyling
- Department of Medicine III, Ludwig-Maximilians-University Hospital, Munich, Germany
| | - David W Scott
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Jane N Winter
- Feinberg School of Medicine, Northwestern University, Chicago, IL; and
| | - Andrew D Zelenetz
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- Weill Medical College, Cornell University, New York, NY
| |
Collapse
|
5
|
Giuliani F, Pavlovsky MA, Giere I, Fernandez I, Sackmann F, Pavlovsky A, Remaggi G, Castillo JJ. First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia. Ann Hematol 2022; 101:2365-2367. [PMID: 35794278 DOI: 10.1007/s00277-022-04910-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 06/25/2022] [Indexed: 11/29/2022]
Affiliation(s)
- F Giuliani
- Fundaleu, Haematology Service, Buenos Aires, Argentina. .,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina.
| | - M A Pavlovsky
- Fundaleu, Haematology Service, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - I Giere
- Fundaleu, Haematology Service, Buenos Aires, Argentina
| | - I Fernandez
- Fundaleu, Haematology Service, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - F Sackmann
- Fundaleu, Haematology Service, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - A Pavlovsky
- Fundaleu, Haematology Service, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - G Remaggi
- Fundaleu, Haematology Service, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - J J Castillo
- Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
6
|
Stanganelli C, Torres DC, Ortega C, Márquez ME, Remedi V, Cabrera J, Mardaraz C, Galvano C, Krzywinski A, Lang C, Zanella L, Agriello E, Bezares R, Pavlovsky A, Pavlovsky MA, Oppezzo P, Slavutsky I. Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients. Ann Hematol 2022; 101:341-348. [PMID: 34713310 DOI: 10.1007/s00277-021-04703-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 10/18/2021] [Indexed: 11/28/2022]
Abstract
Chronic lymphocytic leukemia (CLL) is the most common mature B-cell neoplasm in the West. IGHV4-34 is one of the most frequently used genes in CLL patients, which usually display an indolent outcome. In this study, we explored the mutational profile of CLL patients expressing IGHV4-34 within different stereotypes and their association with prognostic factors and clinical outcome. A multi-institutional cohort of unselected 1444 CLL patients was analyzed by RT-PCR and bidirectional sequencing. Cytogenetics and molecular cytogenetics analyses were also performed. We identified 144 (10%) IGHV4-34 expressing cases, 119 mutated (M), 44 of them with stereotyped B-cell receptors. Subset #4 was the most frequent (56.8% of cases) followed by subsets #16 (13.6%), #29 (6.8%), and #201 (2.3%), with different distribution among countries. Analysis of somatic hypermutation profile showed significant differences among stereotyped subsets for G28>D/E, P45>S, E55>Q, and S64>I changes (p < 0.01) and high frequency of disruption of the glycosylation motif in the VH CDR2 region. All stereotyped IGHV4-34 cases showed normal karyotypes. Deletion 13q14 as a sole alteration was present in 42.8% of stereotyped cases with a different distribution among subsets. A shorter time to first treatment was found in non-stereotyped vs. stereotyped M-IGHV4-34 patients (p = 0.034). Our results add new information supporting the importance of recurrent amino acid changes at particular positions, contributing to refine the molecular characterization of South American CLL patients.
Collapse
Affiliation(s)
- Carmen Stanganelli
- División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.
| | - Davi Coe Torres
- Instituto Nacional de Câncer, Río de Janeiro, RJ, Brazil
- Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
| | - Claudia Ortega
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - María Elena Márquez
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
- Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela
| | - Victoria Remedi
- Hospital Maciel, Administración Servicios de Salud del Estado, Ministerio de Salud, Montevideo, Uruguay
| | - Juana Cabrera
- División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina
| | | | - Camila Galvano
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| | - Andrea Krzywinski
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| | - Cecilia Lang
- Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina
| | - Lorena Zanella
- Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina
| | | | - Raimundo Bezares
- Hospital General de Agudos Teodoro Álvarez, Buenos Aires, Argentina
| | | | | | - Pablo Oppezzo
- Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay
| | - Irma Slavutsky
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina
| |
Collapse
|
7
|
Iorio J, Eleta M, Plates V, Fiad L, Riddick M, Pavlovsky A. MTV, TLG AND SUV MAX AS PROMISING PARAMETERS TO PREDICT EARLY RESPONSE IN PATIENTS WITH HL TREATED WITH ABVD. A RETROSPECTIVE SUB‐ANALYSIS OF THE GATLA‐LH‐05 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.114_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Iorio
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| | - M. Eleta
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| | - V. Plates
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| | - L. Fiad
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| | - M. Riddick
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| | - A. Pavlovsky
- IMAXE, Imagenes, CIUDAD DE BUENOS AIRES RECOLETA Argentina
| |
Collapse
|
8
|
Pavlovsky A, Fiad L, Fernandez I, Prates V, Kurgansky N, Cerutti A, Sackman F, Negri F, Zoppegno L, Negri P, Remaggi G, Ferrari L, Mariano R, Guanchiale L, Maradei J, Rudoy S, Giuliani F, Roveri E, Enrico A, Zabaljauregui S, Cabrejo M, Gumpel C, Quartara A, Gonzalez CM, Varela A, Riddick M, Pavlovsky S. PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.108_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - L. Fiad
- Hospital Italiano La Plata Hematology Buenos Aires Argentina
| | | | - V. Prates
- Hospital Italiano La Plata Hematology Buenos Aires Argentina
| | | | - A. Cerutti
- IDHEA Clínica Hematológica Hematology Rosario, Santa Fe Argentina
| | - F. Sackman
- Fundaleu Hematology Buenos Aires Argentina
| | - F. Negri
- Instituto Privado de Hematología y Hemoterapia Hematology Paraná, Entre Ríos Argentina
| | - L. Zoppegno
- HIGA General José de San Martín La Plata Hematology Buenos Aires Argentina
| | - P. Negri
- Instituto Privado de Hematología y Hemoterapia Hematology Paraná, Entre Ríos Argentina
| | - G. Remaggi
- Fundaleu Hematology Buenos Aires Argentina
| | - L. Ferrari
- Fundaleu Hematology Buenos Aires Argentina
| | - R. Mariano
- Hospital San Martín Hematology Paraná, Entre Ríos, California Argentina
| | - L. Guanchiale
- Hospital Universitario Privado de Córdoba Hematology Córdoba Argentina
| | - J. Maradei
- Hospital Municipal Dr. E. Ferreyra Hematology Necochea, Buenos Aires Argentina
| | - S. Rudoy
- Clínica Modelo de Morón Hematology Buenos Aires Argentina
| | | | - E. Roveri
- Hospital Provincial del Centenario Hematology Rosario, Santa Fe Argentina
| | - A. Enrico
- Hospital Italiano La PLata Hematology Buenos Aires Argentina
| | - S. Zabaljauregui
- Instituto de Investigaciones Hematológicas Mariano R. Castex Hematology Buenos Aires Argentina
| | - M. Cabrejo
- Sanatorio Municipal Julio Méndez Hematology Buenos Aires Argentina
| | - C. Gumpel
- Sanatorio Plaza Hematology Rosario, Santa Fe Argentina
| | - A. Quartara
- Hospital Provincial del Centenario Hematology Rosario, Santa Fe Argentina
| | - C. M. Gonzalez
- Instituto de Investigaciones Hematológicas Mariano R. Castex Hematology Buenos Aires Argentina
| | - A. Varela
- Sanatorio Las Lomas Hematology Buenos Aires Argentina
| | - M. Riddick
- Departamento de Matematicas‐Facultad de Ciencias Exactas‐ UNLP‐CONICET Mathematics Buenos Aires Argentina
| | | |
Collapse
|
9
|
Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, Skrypets T, De Souza CA, Hawkes EA, Fiad L, Lymboussakis A, Tomuleasa C, Nair R, Pereira J, Pereyra P, Minoia C, Kryachok I, de Castro NS, Advani RH, Luminari S. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0. Hematol Oncol 2021. [DOI: 10.1002/hon.135_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Federico
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C. S Chiattone
- Santa Casa de Sao Paulo School of Medical Sciences São Paulo Brazil
| | - H. M Prince
- Epworth Healthcare, East Melbourne Richmond Australia
| | - A Pavlovsky
- Fundaleu, Haematology Buenos Aires Argentina
| | - M Manni
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - M Civallero
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - T Skrypets
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - E. A Hawkes
- Lymphoma and Related Diseases Registry School of Public Health and Preventive Medicine Monash University and Olivia Newton John Cancer Research Institute Austin Health, Melbourne Australia
| | - L Fiad
- Hospital Italiano La Plata Department of Hematology and Oncology Buenos Aires Argentina
| | - A Lymboussakis
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C Tomuleasa
- Ion Chiricuta Oncology Institute Department of Hematology Cluj Napoca Romania
| | - R Nair
- TATA Medical Center, Clinical Haematology Oncology Kolkata India
| | - J Pereira
- Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina São Paulo Brazil
| | - P Pereyra
- Hospital Nacional Dr. Prof. Alejandro Posadas Hematology Buenos Aires Argentina
| | - C Minoia
- IRCCS Cancer Institute "Giovanni Paolo II" Haematology Unit Bari Italy
| | - I Kryachok
- National Cancer Institute Oncohematology Department Kiev Ukraine
| | - N. S de Castro
- Hospital de Cancer de Barretos, Hematology, Barretos São Paulo Brazil
| | - R. H Advani
- Stanford Cancer Center Blood and Marrow Transplant Program, Stanford California USA
| | - S Luminari
- Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| |
Collapse
|
10
|
Basquiera AL, García MJ, Martinez Rolón J, Olmedo J, Laviano J, Burgos R, Caeiro G, Remaggi G, Raña P, Paoletti M, González CM, Fernández I, Pavlovsky A, Perusini MA, Rodriguez A, Guanchiale L, Carvani A, Mandrile L, Figueroa F, Vicente Reparaz A, Fragapane Mathus PN, Garate G, Fauque ME, Kantor G, Cruset S, Gonzalez Lorch JS, Szelagowski M, Giarini MP, Oliveira N, García MC, Ventriglia MV, Pereyra PH, Gutierrez DR, Kusminsky G, Troccoli J, Freitas MJ, Cranco S, Del V Sanchez N, Rey I, Funes ME, Jarchum S, Freue J, Miroli A, Guerrero O, López Ares L, Campestri R, Bove V, Salinas GN, Cabrejo M, Milone JH, Zabaljauregui S, Gotta D, Dupont JC, Stemmelin G. Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology. Medicina (B Aires) 2021; 81:536-545. [PMID: 34453794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.
Collapse
Affiliation(s)
- Ana L Basquiera
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail:
| | - Mercedes J García
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | | | | | - Rubén Burgos
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | - Gastón Caeiro
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | - Pablo Raña
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | | | | | | | | | | | | | | | - Analia Carvani
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | - Laura Mandrile
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | | | | | | | | | | | | | - Soledad Cruset
- Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | - María J Freitas
- Hospital Nacional Posadas, El Palomar, Buenos Aires, Argentina
| | | | | | - Irene Rey
- Hospital Ramos Mejía, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | - Victor Bove
- Instituto Oncohematológico Privado, Río Cuarto, Córdoba, Argentina
| | | | - María Cabrejo
- Sanatorio Municipal Julio Méndez, Buenos Aires, Argentina
| | | | | | - Daniel Gotta
- Hospital Urquiza, Concepción del Uruguay, Entre Ríos, Argentina
| | | | | |
Collapse
|
11
|
Bentolila G, Pavlovsky A. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation. Leuk Lymphoma 2020; 61:1548-1554. [PMID: 32148142 DOI: 10.1080/10428194.2020.1732959] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The treatment of classic Hodgkin lymphoma (HL) is a success in onco-hematology. Despite the high cure rate of HL with initial therapy, 5-10% of patients are primary refractory and 10-20% will eventually relapse. The standard treatment for these patients is salvage chemotherapy and autologous stem cell transplantation (ASCT). Only about half of these patients will benefit from this procedure. The prognosis of relapsed refractory (rr) HL has improved with the introduction of effective drugs. With these options available, identification of reliable risk factors is important to guide treatment over the course of disease. Different variables including performance status, anemia, B symptoms, laboratory abnormalities, treatment intensity before ASCT, response to therapy, and duration of remission, have been analyzed to determine risk for progression-free survival (PFS) and overall survival (OS) after ASCT. This review will discuss the publications analyzing these factors, the validated risk scores useful to identify patients at high risk of progression after ASCT, and will describe future perspectives.
Collapse
Affiliation(s)
| | - Astrid Pavlovsky
- FUNDALEU: Fundacion contra la Leucemia, Buenos Aires, Argentina.,Centro de Hematologia Pavlovsky, Buenos Aires, Argentina.,GATLA: Grupo Argentino de Tratamiento de Leucemia Aguda, Buenos Aires, Argentina
| |
Collapse
|
12
|
Mardaraz C, Sackmann F, Pavlovsky C, Pavlovsky M, Zerga M, Mela Osorio M, Bullorsky E, Pavlovsky A. RESULTS OF MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE GENES ANALYSIS IN A COHORT OF PATIENTS WITH B-CLL. A SINGLE CENTRE EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.44_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Mardaraz
- Clinical research; Centro de Hematología Pavlovsky; Buenos Aires Argentina
| | - F. Sackmann
- Clinical research; Centro de Hematología Pavlovsky; Buenos Aires Argentina
| | - C. Pavlovsky
- Clinical research; Centro de Hematología Pavlovsky; Buenos Aires Argentina
| | - M. Pavlovsky
- Clinical research; Centro de Hematología Pavlovsky; Buenos Aires Argentina
| | - M. Zerga
- Hematology Department; Hospital Alemán; Buenos Aires Argentina
| | | | - E. Bullorsky
- Hematology Department; Hospital Britanico; Buenos Aires Argentina
| | - A. Pavlovsky
- Clinical research; Centro de Hematología Pavlovsky; Buenos Aires Argentina
| |
Collapse
|
13
|
Nili Gal Yam E, Zundelevich A, Dadiani M, Itay A, Sela T, Gadot M, Kahana S, Pavlovsky A, Barshack I, Kaufman B. ESR1 mutations are similarly prevalent in newly metastatic and loco-regional recurrence of endocrine-treated breast cancer patients and carry worse prognosis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz095.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, Milone G, Cerutti I, Zabaljauregui S, Mariano R, Grecco HF, Basquiera AL, Saba S, Rudoy S, Sackmann F, Castano V, Remaggi G, Cabrejo M, Roveri E, Casale MF, Cabane V, Taus R, Venturini C, Sakamoto F, Varela AI, Riddick M, Pavlovsky S. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial. Br J Haematol 2019; 185:865-873. [PMID: 30864146 DOI: 10.1111/bjh.15838] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2018] [Accepted: 01/09/2019] [Indexed: 12/01/2022]
Abstract
The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I-IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3-negative patients received no further therapy. PET3-positive patients received three additional cycles of ABVD plus involved-field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re-evaluated by PET scan (PET6). Study endpoints were 3-year progression-free survival (PFS) and overall survival (OS) rates. Two hundred and thirty-nine patients with early-stage and 138 with advanced-stage were evaluable. Overall, 260 patients (70%) were PET3-negative and had higher 3-year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET3-positive patients. All PET3-negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90-91%; P = 0·76) and OS (97-99%). The only independent prognostic factor for PFS was PET3-negativity (Hazard ratio 3·8; 95% confidence interval 2·4-6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.
Collapse
Affiliation(s)
- Astrid Pavlovsky
- Haematology, Fundaleu, Buenos Aires, Argentina.,Haematology, Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | - Isolda Fernandez
- Haematology, Fundaleu, Buenos Aires, Argentina.,Haematology, Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | | | - Virginia Prates
- Haematology, Hospital Italiano de la Plata, La Plata, Argentina
| | - Lucia Zoppegno
- Haematology, Hospital san Martin de la Plata, La Plata, Argentina
| | - Pedro Negri
- Haematology, Instituto Privado de Hematologia y Hemoterapia, Paraná, Entre Rios, Argentina
| | | | - Ider Cerutti
- Haematology, IDHeA, Rosario, Santa Fe, Argentina
| | | | - Romina Mariano
- Haematology, Hospital San Martin, Paraná, Entre Rios, Argentina
| | | | - Ana L Basquiera
- Haematology, Hospital Privado de Cordoba, Cordoba, Argentina
| | - Silvia Saba
- Bone Marrow Transplantation Unit, Hospital Rossi, La Plata, Argentina
| | - Silvia Rudoy
- Haematology, Clinica Modelo Moron, Buenos Aires, Argentina
| | - Federico Sackmann
- Haematology, Fundaleu, Buenos Aires, Argentina.,Haematology, Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | | | - Guillermina Remaggi
- Haematology, Centro de Hematologia Pavlovsky, Buenos Aires, Argentina.,Transplantation Program, Fundaleu, Buenos Aires, Argentina
| | - Maria Cabrejo
- Haematology, Sanatorio Julio Mendez, Buenos Aires, Argentina
| | | | - Maria F Casale
- Haematology, Hospital General Centeno, Gral Pico, La Pampa, Argentina
| | - Vanina Cabane
- Haematology, Clínica Dr. Roberto Raña, Neuquen, Argentina
| | - Rossana Taus
- Bone Marrow Transplantation Unit, Hospital Rossi, La Plata, Argentina
| | - Claudia Venturini
- Haematology, Instituto Privado de Hematologia y Hemoterapia, Paraná, Entre Rios, Argentina
| | - Francisco Sakamoto
- Haematology, Instituto Privado de Hematologia y Hemoterapia, Paraná, Entre Rios, Argentina
| | - Ana I Varela
- Haematology, Sanatorio Las Lomas, Buenos Aires, Argentina
| | - Maximiliano Riddick
- Departamento de Matematicas-Facultad de Ciencias Exactas-UNLP-CONICET, Buenos Aires, Argentina
| | - Santiago Pavlovsky
- Haematology, Fundaleu, Buenos Aires, Argentina.,Haematology, Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
| | | |
Collapse
|
15
|
Mela Osorio MJ, Pavlovsky C, Pavlovsky A, Fernandez I, Massa FS, Ferrari L, Juni M, Riddick M, Pavlovsky MA. Impact of Ibrutinib in Quality of Life (QoL) in Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of Real-World Experience. Clinical Lymphoma Myeloma and Leukemia 2018. [DOI: 10.1016/j.clml.2018.07.085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Pavlovsky A, Peterson H, Casillas G, Simonetti C, Martinez Canaveri A, Andino Pavlovsky A. Use of Factor VIII in the Treatment of Hemophilia. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1655471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThis publication describes the results obtained by treatment of haemophiliacs with factor VIII preparations isolated from Cohn fraction I by use of tannic acid, FI-O-Ta.The authors stress the rapidity of the disappearance of factor VIII after injection. Transfusions are generally well tolerated. One reaction of the pyrogen type has been observed and also a case of activation of the fibrinolytic system.A second purification method by means of chromatography on DEAE-cellulose is described.
Collapse
|
17
|
Fox C, Bellei M, Manni M, Kim S, Ko Y, Shustov A, Cabrera M, Chiattone C, Horwitz S, Spina M, Advani R, Angrilli F, De Souza C, Dlouhy I, Fernandez-Alvarez R, Gabús R, Hitz F, Laszlo D, Montoto S, Nagler A, Pavlovsky A, Vitolo U, Zoppegno L, Federico M, Kim W. IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C.P. Fox
- Nottingham University Hospitals NHS Trust, and Institute of Cancer Sciences, University of Birmingham; Nottingham UK
| | - M. Bellei
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - S.J. Kim
- Division of Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - Y.H. Ko
- Department of Pathology; Sungkyunkwan University; Seoul Republic of Korea
| | - A.R. Shustov
- Division of Hematology, FHCRC; University of Washington Medical Center; Seattle USA
| | - M.E. Cabrera
- Sección Hematología, Hospital del Salvador; Universidad de Chile; Santiago de Chile Chile
| | - C.S. Chiattone
- Departamento de Clínica Médica, FCM da Santa Casa de São Paulo; Centro de Linfomas Núcleo de Oncologia Hospital Samaritano; São Paulo Brazil
| | - S.M. Horwitz
- Dept. Medicine; Memorial Sloan-Kettering Cancer Center; New York USA
| | - M. Spina
- Medical Oncology A; Aviano National Cancer Institute; Aviano Italy
| | - R.H. Advani
- Division of Oncology; Stanford University School of Medicine; Stanford USA
| | - F. Angrilli
- Dip. Ematologia, Medicina Trasfusionale e Biotecnologie; UOSD Centro Diagnosi e Terapia Linfomi; PO Pescara, Pescara Italy
| | - C.A. De Souza
- Departamento de Clínica Médica; Universidade Estadual de Campinas; Campinas Brazil
| | - I. Dlouhy
- Hematology Department; Hospital Clinic; Barcelona Italy
| | | | - R. Gabús
- Service of Hematology and Bone Marrow Transplantation; Hospital Maciel; Montevideo Uruguay
| | - F. Hitz
- Department of Oncology/Haematology; Cantonal Hospital; St Gallen Switzerland
| | - D. Laszlo
- Division of Haemato-Oncology; IEO - Istituto Europeo di Oncologia; Milan Italy
| | - S. Montoto
- Department of Haematology; Barts Health NHS Trust; London Italy
| | - A. Nagler
- Department of Bone Marrow Transplantation; Tel-Aviv University; Tel-Aviv Israel
| | | | - U. Vitolo
- S.C. Ematologia, Dipartimento di Oncologia ed Ematologia, S.C. Ematologia, Dipartimento di Oncologia ed Ematologia; Torino Italy
| | - L. Zoppegno
- Hematologia, Hospital provincial San Martín de La Plata; Buenos Aires Argentina
| | - M. Federico
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - W.S. Kim
- Division of Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| |
Collapse
|
18
|
Ciliberti E, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, Milone G, Cerutti I, Zabaljauregui S, Mariano R, Fernandez Grecco H, Saba S, Sackmann F, Castano V, Remaggi G, Cabrejo M, Rudoy S, Roveri E, Cabane V, Gumpel C, Taus R, Casale M, Taus R, Sakamoto F, Pavlovsky A. SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - N. Kurgansky
- Hematology; GATLA - Santa Fe; Santa Fe Argentina
| | - V. Prates
- Hematology; GATLA; La Plata Argentina
| | | | - P. Negri
- Hematology; GATLA - Entre Rios; Paraná Argentina
| | - G. Milone
- Hematology; GATLA; Buenos Aires Argentina
| | - I. Cerutti
- Hematology; GATLA - Santa Fe; Rosario Argentina
| | | | - R. Mariano
- Hematology; GATLA - Entre Rios; Paraná Argentina
| | | | - S. Saba
- Hematology; GATLA; La Plata Argentina
| | | | - V. Castano
- Hematology; GATLA; Buenos Aires Argentina
| | - G. Remaggi
- Hematology; GATLA; Buenos Aires Argentina
| | - M. Cabrejo
- Hematology; GATLA; Buenos Aires Argentina
| | - S. Rudoy
- Hematology; GATLA; Buenos Aires Argentina
| | - E. Roveri
- Hematology; GATLA; Buenos Aires Argentina
| | - V. Cabane
- Hematology; GATLA; Neuquen Argentina
| | - C. Gumpel
- Hematology; GATLA - Santa Fe; Rosario Argentina
| | - R. Taus
- Hematology; GATLA; La Plata Argentina
| | - M. Casale
- Hematology; GATLA; Buenos Aires Argentina
| | - R. Taus
- Hematology; GATLA - Entre Rios; Paraná Argentina
| | - F. Sakamoto
- Hematology; GATLA - Entre Rios; Paraná Argentina
| | | |
Collapse
|
19
|
Negri Aranguren M, Shanley C, Cranco S, Otero V, Fiad L, Fernandez I, Miodosky M, Kusminsky G, Corso A, Bistmans A, Huber M, Marull M, Jarchum S, Guanchiale L, Marquez M, Beligoy L, Cerutti I, Navieckas A, Tamashiro M, Pujol M, Taus R, Canosa V, Lopez Galletti L, Prates M, Riddick M, Pavlovsky A. Brentuximab vedotin: A retrospective multicenter analysis of its indication, safety and efficacy in Argentina. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | - C. Shanley
- Hematology; Htal. Britanico Buenos Aires; Caba Argentina
| | - S. Cranco
- Hematology; Instituto Alexander Fleming; Caba Argentina
| | - V. Otero
- Hematology; Htal. Italiano Buenos Aires; Caba Argentina
| | - L. Fiad
- Hematology; Htal. Italiano De La Plata; La Plata Argentina
| | | | | | | | - A. Corso
- Hematology, Htal. De Clinicas; Caba Argentina
| | - A. Bistmans
- Hematology, Htal. Ramos Mejia; Caba Argentina
| | - M. Huber
- Hematology, Cemic; Caba Argentina
| | - M. Marull
- Hematology, Centro Posadas; Posadas Argentina
| | - S. Jarchum
- Hematology, Sanatorio Allende; Cordoba Argentina
| | | | | | - L. Beligoy
- Hematology; Hospital Perrando; Chaco Argentina
| | | | - A. Navieckas
- Hematology, Htal. Del Cruce; Florencio Varela Argentina
| | - M. Tamashiro
- Hematology; Sanatorio Sagrado Corazon; Caba Argentina
| | - M. Pujol
- Hematology, Htal Angela I. De Llano; Corrientes Argentina
| | - R. Taus
- Hematology, Htal. Rossi; La Plata Argentina
| | - V. Canosa
- Hematology, Htal. Lagomaggiore; Mendoza Argentina
| | | | - M.V. Prates
- Hematology; Htal. Italiano De La Plata; La Plata Argentina
| | - M. Riddick
- Ciencias Exactas, Unlp; La Plata Argentina
| | - A. Pavlovsky
- Hematology; Centro Hematologia Pavlovsky; Caba Argentina
| |
Collapse
|
20
|
Roisman A, Huamán Garaicoa F, Metrebian F, Narbaitz M, Kohan D, García Rivello H, Fernandez I, Pavlovsky A, Pavlovsky M, Hernández L, Slavutsky I. SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. Genes Chromosomes Cancer 2016; 55:531-40. [PMID: 26998831 DOI: 10.1002/gcc.22355] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 03/03/2016] [Accepted: 03/14/2016] [Indexed: 12/12/2022] Open
Abstract
Mantle cell lymphoma (MCL) is a heterogeneous B-cell lymphoid malignancy where most patients follow an aggressive clinical course whereas others are associated with an indolent performance. SOX4, SOX11, and SOX12 belong to SOXC family of transcription factors involved in embryonic neurogenesis and tissue remodeling. Among them, SOX11 has been found aberrantly expressed in most aggressive MCL patients, being considered a reliable biomarker in the pathology. Several studies have revealed that microRNAs (miRs) from the miR-17-92 cluster are among the most deregulated miRNAs in human cancers, still little is known about this cluster in MCL. In this study we screened the transcriptional profiles of 70 MCL patients for SOXC cluster and miR17, miR18a, miR19b and miR92a, from the miR-17-92 cluster. Gene expression analysis showed higher SOX11 and SOX12 levels compared to SOX4 (P ≤ 0.0026). Moreover we found a negative correlation between the expression of SOX11 and SOX4 (P < 0.0001). miR17-92 cluster analysis showed that miR19b and miR92a exhibited higher levels than miR17 and miR18a (P < 0.0001). Unsupervised hierarchical clustering revealed two subgroups with significant differences in relation to aggressive MCL features, such as blastoid morphological variant (P = 0.0412), nodal presentation (P = 0.0492), CD5(+) (P = 0.0004) and shorter overall survival (P < 0.0001). Together, our findings show for the first time an association between the differential expression profiles of SOXC and miR17-92 clusters in MCL and also relate them to different clinical subtypes of the disease adding new biological information that may contribute to a better understanding of this pathology. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Alejandro Roisman
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
| | - Fuad Huamán Garaicoa
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina.,FUNDALEU, Buenos Aires, Argentina
| | - Fernanda Metrebian
- División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
| | - Marina Narbaitz
- FUNDALEU, Buenos Aires, Argentina.,División Patología, Instituto de Investigaciones Hematológicas, ANM, Buenos Aires, Argentina
| | - Dana Kohan
- Servicio de Patología, Hospital Italiano, Buenos Aires, Argentina
| | | | | | | | | | - Luis Hernández
- Patología Molecular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España
| | - Irma Slavutsky
- Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-Academia Nacional de Medicina (ANM), Buenos Aires, Argentina
| |
Collapse
|
21
|
Martinez Canaveri A, Pavlovsky A, De Tezanos Pinto M. The detection of hemophilia carriers. Bibl Haematol 2015; 26:41-6. [PMID: 5955562 DOI: 10.1159/000384527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
22
|
Pavlovsky A, Andino A, De Tezanos Pinto M. Treatment of haemophilia A. Bibl Haematol 2015; 23:1303-6. [PMID: 5885220 DOI: 10.1159/000384460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
23
|
Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. T-cell lymphomas in South america and europe. Rev Bras Hematol Hemoter 2012; 34:42-7. [PMID: 23049383 PMCID: PMC3459617 DOI: 10.5581/1516-8484.20120013] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2011] [Accepted: 12/04/2011] [Indexed: 02/04/2023] Open
Abstract
Peripheral T-cell lymphomas are a group of rare neoplasms originating from clonal proliferation of mature post-thymic lymphocytes with different entities having specific biological characteristics and clinical features. As natural killer cells are closely related to T-cells, natural killer-cell lymphomas are also part of the group. The current World Health Organization classification recognizes four categories of T/natural killer-cell lymphomas with respect to their presentation: disseminated (leukemic), nodal, extranodal and cutaneous. Geographic variations in the distribution of these diseases are well documented: nodal subtypes are more frequent in Europe and North America, while extranodal forms, including natural killer-cell lymphomas, occur almost exclusively in Asia and South America. On the whole, T-cell lymphomas are more common in Asia than in western countries, usually affect adults, with a higher tendency in men, and, excluding a few subtypes, usually have an aggressive course and poor prognosis. Apart from anaplastic lymphoma kinase-positive anaplastic large cell lymphoma, that have a good outcome, other nodal and extranodal forms have a 5-year overall survival of about 30%. According to the principal prognostic indexes, the majority of patients are allocated to the unfavorable subset. In the past, the rarity of these diseases prevented progress in the understanding of their biology and improvements in the efficaciousness of therapy. Recently, international projects devoted to these diseases created networks promoting investigations on T-cell lymphomas. These projects are the basis of forthcoming cooperative, large scale trials to detail biologic characteristics of each sub-entity and to possibly individuate targets for new therapies.
Collapse
Affiliation(s)
- Monica Bellei
- Department of Oncology, Hematology and Respiratory Diseases, L'Università di Modena e Reggio Emilia - UniMoRe, Modena, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Alejandre ME, Pavlovsky MA, Remaggi G, Corrado C, Fernandez I, Milone G, Pavlovsky A, Madalena L, Pandolfo M, Facio ML, Bresciani P, Pavlovsky S, Pizzolato MA. Serum free light chains and oligoclonal bands in patients with multiple myeloma and autologous stem cell transplantation. Clin Chem Lab Med 2012; 50:1093-7. [DOI: 10.1515/cclm-2011-0544] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2011] [Accepted: 03/26/2012] [Indexed: 11/15/2022]
|
25
|
Pavlovsky C, Pardo L, Pavlovsky MA, Corrado C, Sapia S, Mountford P, Monreal M, Fernandez I, Milone G, Pavlovsky A, Juni M, Pavlovsky S. Is assessment of surface CD38 expression worthwhile as a prognostic factor in chronic lymphocytic leukemia patients? Hematology 2008; 13:24-7. [PMID: 18534062 DOI: 10.1179/102453308x315780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
We studied the clinical impact of CD38 expression in 226 chronic lymphocytic leukemia patients (CLL) at disease presentation and during follow up to determine its prognostic significance, progression free survival (PFS) and overall survival (OS), and to verify whether this parameter changed over time. Various patients' characteristics were studied including gender, Rai and Binet stages, immunoglobulin light chain expression, lymphocyte doubling time and CD38 expression. After a median follow up of 53 months (range 6-282), 62% CD38 positive(+) patients required therapy. PFS and OS at 84 months were significantly lower for CD38(+) patients: 20 and 71% respectively, compared to CD38 negative(-): 70 and 96%. At multivariate analysis CD38(+) showed to be the best factor for predicting progression: HR 3.3, 95%CI 2.10-5.14, p = 0.000. Its expression did not change in 98% re-evaluated patients. We confirm that CD38(+) is a stable parameter for the identification of CLL patients with a more aggressive disease course.
Collapse
|
26
|
Sackmann Massa F, Corrado C, Fernandez I, Mountford P, Pavlovsky A, Remaggi G, Intile D, Alejandre M, Pizzolato M, Pavlovsky S. Gammopathy of undetermined significance: Identification of prognostic factors and survival. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Ferreri AJM, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalbán C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A, Pertoldi B, Horváth B, Szomor A, Zucca E, Cavalli F, Ponzoni M. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007; 92:486-92. [PMID: 17488659 DOI: 10.3324/haematol.10829] [Citation(s) in RCA: 112] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND AND OBJECTIVES This study explored variations in the clinical manifestations of intravascular lymphoma (IVL) on the bases of the association with hemophagocytosis and the country where the diagnosis was made. DESIGN AND METHODS The clinical features of 50 Western patients with IVL were compared with those of 123 patients with IVL diagnosed in Eastern countries (87 diagnosed in Japan and 36 in other Asian countries), previously reported in English literature, and collected by an electronic bibliographic search. RESULTS Hemophagocytosis was absent in Western patients, but reported in 38 (44%) Japanese patients (p=0.00001) and in seven (19%) patients from other Asian countries (p=0.002). No clinical differences were evident between patients with hemophagocytosis-negative IVL diagnosed in Western countries, Japan and other Asian Countries. Conversely, Japanese and non-Japanese patients with hemophagocytosis-related IVL more frequently had stage IV disease, fever, hepato-splenic involvement, marrow infiltration, dyspnea, anemia, and thrombocytopenia, and rarely exhibited cutaneous or central nervous system involvement. Lymph node and peripheral blood involvement was uncommon in all subgroups. In Western patients, anthracycline-based chemotherapy was associated with a 52% remission rate, and a 2-year overall survival of 46%. INTERPRETATION AND CONCLUSIONS The clinical features of IVL vary according to the association with hemophagocytosis, regardless of the country in which the diagnosis is made. Western, Japanese and other Asian patients with hemophagocytosis-negative IVL display similar clinical characteristics and should be considered as having classical IVL. Patients with hemophagocytosis-related IVL show significantly different clinical features. Both forms have a poor prognosis. Extensive molecular studies are needed to explore whether these clinical differences might reflect discordant biological entities within IVL.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anthracyclines/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Asia/epidemiology
- Asian People/statistics & numerical data
- Brain Neoplasms/epidemiology
- Brain Neoplasms/ethnology
- Brain Neoplasms/pathology
- Disease Progression
- Europe/epidemiology
- Female
- Follow-Up Studies
- Forecasting
- Humans
- Japan/ethnology
- Lymphohistiocytosis, Hemophagocytic/diagnosis
- Lymphohistiocytosis, Hemophagocytic/epidemiology
- Lymphohistiocytosis, Hemophagocytic/ethnology
- Lymphohistiocytosis, Hemophagocytic/etiology
- Lymphoma, Large B-Cell, Diffuse/classification
- Lymphoma, Large B-Cell, Diffuse/complications
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/epidemiology
- Lymphoma, Large B-Cell, Diffuse/ethnology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Male
- Middle Aged
- Organ Specificity
- Phenotype
- Prognosis
- Retrospective Studies
- Skin Neoplasms/epidemiology
- Skin Neoplasms/ethnology
- Skin Neoplasms/pathology
- Surveys and Questionnaires
- Treatment Outcome
- Vascular Neoplasms/classification
- Vascular Neoplasms/complications
- Vascular Neoplasms/diagnosis
- Vascular Neoplasms/drug therapy
- Vascular Neoplasms/epidemiology
- Vascular Neoplasms/ethnology
- Vascular Neoplasms/pathology
- White People/statistics & numerical data
Collapse
Affiliation(s)
- Andrés J M Ferreri
- Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy. andres.ferreri@hsr
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Vázquez F, Penchasky D, de la Parra I, Pavlovsky A, Adamczuk Y. [Bilateral internal jugular thrombosis associated with thrombophilia after ovarian induction for infertility]. Medicina (B Aires) 2002; 62:328-30. [PMID: 12325489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
Thromboembolic events are an infrequent complication of hormonal treatment for infertility and are generally related to the hyperstimulated ovarian syndrome (HOS). Jugular vein thrombosis is an unusual site of thrombosis and when present one should look for a predisposing factor. We describe a 31-year-old woman, with no previous medical history, non-smoker, who received a single cycle of hormonal stimulation for in vitro fertilisation due to primary infertility. During her eighth week of a twin pregnancy, she consulted the emergency room where the diagnosis of bilateral jugular thrombosis was confirmed, in absence of HOS or any known predisposing factor. In subsequent studies, the presence of Factor V Leyden and a mutation of G 20210 prothrombin were found. These, in association to the hormonal stimulus, were considered the risk factors. She received anticoagulation treatment with low molecular weight heparin. Screening tests for thrombophilias before hormonal treatment is not recommended, but one could consider this possibility in high-risk patients or in those who develop thrombosis in the absence of any predisposing factors.
Collapse
Affiliation(s)
- Fernando Vázquez
- Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Gascón 450, 1181 Buenos Aires, Argentina.
| | | | | | | | | |
Collapse
|
29
|
Hagen SE, Domagala J, Gajda C, Lovdahl M, Tait BD, Wise E, Holler T, Hupe D, Nouhan C, Urumov A, Zeikus G, Zeikus E, Lunney EA, Pavlovsky A, Gracheck SJ, Saunders J, VanderRoest S, Brodfuehrer J. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J Med Chem 2001; 44:2319-32. [PMID: 11428926 DOI: 10.1021/jm0003844] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species. The search for a suitable back-up candidate centered on the replacement of the aniline moiety at C-6 with an appropriately substituted heterocyle. In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models. The compound with the best combination of high potency, low toxicity, and favorable bioavailabilty was (S)-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-(2-thiophen-3-yl-ethyl)-5,6-dihydro-pyran-2-one (13-(S)). This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation.
Collapse
Affiliation(s)
- S E Hagen
- Department of Chemistry, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Mejía R, Oriolo M, Militello C, Pavlovsky A, González Toledo E. [Images in medicine. Thromboembolic renal infarct]. Medicina (B Aires) 2001; 61:183. [PMID: 11405195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
|
31
|
Semenov SY, Simonova GI, Starostin AN, Taran MG, Souvorov AE, Bulyshev AE, Svenson RH, Nazarov AG, Sizov YE, Posukh VG, Pavlovsky A, Tatsis GP. Dielectrical model of cellular structures in radio frequency and microwave spectrum. Electrically interacting versus noninteracting cells. Ann Biomed Eng 2001; 29:427-35. [PMID: 11400723 DOI: 10.1114/1.1366675] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A model of dielectrical properties of cellular structures of a tissue has been proposed. Cellular structures were presented as a composition of membrane covered spheres and cylinders that do not interact with each other. No restrictions were applied to the thickness of cellular membranes. The model was further generalized into a case of electrically interacting cells. The difference in dielectrical properties calculated with the model of electrically noninteracting versus interacting cells is inversely dependent on frequency. At biological values of cellular volume fraction near 0.7 (packed configuration) the difference is about 10%-15% in resistance and in epsilon' for frequencies near 0.1 MHz. Experimental data for myocardial tissue and theoretical data, for both interacting and noninteracting models, reasonably agree at frequencies of 1-100 MHz.
Collapse
Affiliation(s)
- S Y Semenov
- Laser and Applied Technologies Laboratory, Carolinas Heart Institute and Carolinas Medical Center, Charlotte, NC 28203-2861, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Semenov SY, Svenson RH, Bulyshev AE, Souvorov AE, Nazarov AG, Sizov YE, Posukh VG, Pavlovsky A, Tatsis GP. Microwave spectroscopy of myocardial ischemia and infarction. 2. Biophysical reconstruction. Ann Biomed Eng 2000; 28:55-60. [PMID: 10645788 DOI: 10.1114/1.254] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The proposed dielectrical relaxation model of the myocardium in the microwave spectrum has been verified both on test solutions and on normal canine myocardium. Furthermore, the model was utilized to reconstruct the changes in tissue properties (including myocardial bulk resistance and water content) following myocardial acute ischemia and chronic infarction. It was shown that the reconstructed myocardial resistance and water content correlate dynamically with the process of the development of acute myocardial ischemic injury. In chronic cases the reconstructed resistance and water content of infarcted myocardium are significantly different from that of normal myocardium: the resistance is lower and water content is higher than in normal myocardium.
Collapse
Affiliation(s)
- S Y Semenov
- Laser and Applied Technologies Laboratory, Carolinas Heart Institute and Carolinas Medical Center, Charlotte, NC 25803-2861, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Prasad JV, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Erickson JW. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. Bioorg Med Chem 1999; 7:2775-800. [PMID: 10658583 DOI: 10.1016/s0968-0896(99)00215-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
With the insight generated by the availability of X-ray crystal structures of various 5,6-dihydropyran-2-ones bound to HIV PR, inhibitors possessing various alkyl groups at the 6-position of 5,6-dihydropyran-2-one ring were synthesized. The inhibitors possessing a 6-alkyl group exhibited superior antiviral activities when compared to 6-phenyl analogues. Antiviral efficacies were further improved upon introduction of a polar group (hydroxyl or amino) on the 4-position of the phenethyl moiety as well as the polar group (hydroxymethyl) on the 3-(tert-butyl-5-methyl-phenylthio) moiety. The polar substitution is also advantageous for decreasing toxicity, providing inhibitors with higher therapeutic indices. The best inhibitor among this series, (S)-6-[2-(4-aminophenyl)-ethyl]-(3-(2-tert-butyl-5-methyl-phenylsulfa nyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one (34S), exhibited an EC50 of 200 nM with a therapeutic index of > 1000. More importantly, these non-peptidic inhibitors, 16S and 34S, appear to offer little cross-resistance to the currently marketed peptidomimetic PR inhibitors. The selected inhibitors tested in vitro against mutant HIV PR showed a very small increase in binding affinities relative to wild-type HIV PR. Cmax and absolute bioavailability of 34S were higher and half-life and time above EC95 were longer compared to 16S. Thus 34S, also known as PD 178390, which displays good antiviral efficacy, promising pharmacokinetic characteristics and favorable activity against mutant enzymes and CYP3A4, has been chosen for further preclinical evaluation.
Collapse
Affiliation(s)
- J V Prasad
- Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Tait BD, Hagen S, Domagala J, Ellsworth EL, Gajda C, Hamilton HW, Prasad JV, Ferguson D, Graham N, Hupe D, Nouhan C, Tummino PJ, Humblet C, Lunney EA, Pavlovsky A, Rubin J, Gracheck SJ, Baldwin ET, Bhat TN, Erickson JW, Gulnik SV, Liu B. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J Med Chem 1997; 40:3781-92. [PMID: 9371244 DOI: 10.1021/jm970615f] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The 4-hydroxy-5,6-dihydropyrone template was utilized as a flexible scaffolding from which to build potent active site inhibitors of HIV protease. Dihydropyrone 1c (5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one) was modeled in the active site of HIV protease utilizing a similar binding mode found for the previously reported 4-hydroxybenzopyran-2-ones. Our model led us to pursue the synthesis of 6,6-disubstituted dihydropyrones with the aim of filling S1 and S2 and thereby increasing the potency of the parent dihydropyrone 1c which did not fill S2. Toward this end we attached various hydrophobic and hydrophilic side chains at the 6-position of the dihydropyrone to mimic the natural and unnatural amino acids known to be effective substrates at P2 and P2'. Parent dihydropyrone 1c (IC50 = 2100 nM) was elaborated into compounds with greater than a 100-fold increase in potency [18c, IC50 = 5 nM, 5-(3,6-dihydro-4-hydroxy-6-oxo-2-phenyl-5-[2-phenylethyl)thio] -2H-pyran-2-yl)pentanoic acid and 12c, IC50 = 51 nM, 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-3- [(2-phenyl-ethyl)thio]-2H-pyran-2-one]. Optimization of the 3-position fragment to fill S1' and S2' afforded potent HIV protease inhibitor 49 [IC50 = 10 nM, 3-[(2-tert-butyl-5-methylphenyl)sulfanyl]-5,6-dihydro-4 -hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one]. The resulting low molecular weight compounds (< 475) have one or no chiral centers and are readily synthesized.
Collapse
Affiliation(s)
- B D Tait
- Department of Chemistry, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Tummino PJ, Prasad JV, Ferguson D, Nouhan C, Graham N, Domagala JM, Ellsworth E, Gajda C, Hagen SE, Lunney EA, Para KS, Tait BD, Pavlovsky A, Erickson JW, Gracheck S, McQuade TJ, Hupe DJ. Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg Med Chem 1996; 4:1401-10. [PMID: 8894098 DOI: 10.1016/0968-0896(96)00134-4] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Several small, achiral nonpeptide inhibitors of HIV-1 protease with low micromolar activity were identified by mass screening of the Parke-Davis compound library. Two of the compounds, structurally similar, were both found to be competitive and reversible inhibitors [compound 1, 4-hydroxy-3-(3-phenoxypropyl)-1-benzopyran-2-one: Ki = 1.0 microM; compound 2, 4-hydroxy-6-phenyl-3-(phenylthio)-pyran-2-one: Ki = 1.1 microM]. These inhibitors were chosen as initial leads for optimization of in vitro inhibitory activity based on molecular modeling and X-ray crystallographic structural data. While improvements in inhibitory potency were small with analogues of compound 1, important X-ray crystallographic structural information of the enzyme-inhibitor complex was gained. When bound, 1 was found to displace H2O301 in the active site while hydrogen bonding to the catalytic Asps and Ile50 and Ile150. The pyranone group of compound 2 was found to bind at the active site in the same manner, with the 6-phenyl and the 3-phenylthio occupying P1 and P1', respectively. The structural information was used to develop design strategies to reach three or four of the internal pockets, P2-P2'. This work led to analogues of diverse structure with high potency (IC50 < 10 nM) that contain either one or no chiral centers and remain nonpeptide. The highly potent compounds possess less anti-HIV activity in cellular assays than expected, and current optimization now focuses on increasing cellular activity. The value of the HIV-1 protease inhibitors described is their potential as better pharmacological agents with a different pattern of viral resistance development, relative to the peptide inhibitors in human clinical trials.
Collapse
Affiliation(s)
- P J Tummino
- Department of Biochemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Vara Prasad J, Pavlovsky A, Para KS, Ellsworth EL, Tummino PJ, Nouhan C, Ferguson D. Nonpeptidic HIV protease inhibitors: 3-(S-benzyl substituted)-4-hydroxy-6-(phenyl substituted)-2H-pyran-2-one with an inverse mode of binding. Bioorg Med Chem Lett 1996. [DOI: 10.1016/0960-894x(96)00185-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB, Rubin JR, Pavlovsky A, Humblet C, Blundell TL. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996; 4:375-86. [PMID: 8740360 DOI: 10.1016/s0969-2126(96)00043-3] [Citation(s) in RCA: 87] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Stromelysin belongs to a family of zinc-dependent endopeptidases referred to as matrix metalloproteinases (MMPs, matrixins) because of their capacity for selective degradation of various components of the extracellular matrix. Matrixins play key roles in diseases as diverse as arthritis and cancer and hence are important targets for therapeutic intervention. RESULTS The crystal structure of the stromelysin catalytic domain (SCD) with bound hydroxamate inhibitor, solved by multiple isomorphous replacement, shows deep S1' specificity pocket which explains differences in inhibitors binding between the collagenases and stromelysin. The binding of calcium ions by loops at the two ends of a beta-strand which marks the boundary of the active site provides a structural rationale for the importance of these cations for stability and catalytic activity. Major differences between the matrixins are clustered in two regions forming the entrance to the active site and hence may be determinants of substrate selectivity. CONCLUSIONS Structural comparisons of SCD with representative members of the metalloproteinase superfamily clearly highlight the conservation of key secondary structural elements, in spite of major variations in the sequences including insertions and deletions of functional domains. However, the three-dimensional structure of SCD, which is generally closely related to the collagenases, shows significant differences not only in the peripheral regions but also in the specificity pockets; these latter differences should facilitate the rational design of specific inhibitors.
Collapse
Affiliation(s)
- V Dhanaraj
- Department of Crystallography, Birkbeck College, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB, Rubin JR, Pavlovsky A, Humblet C, Blundell TL. Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures. Drug Des Discov 1996; 13:3-14. [PMID: 8874040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Structural comparisons of representative members of the zinc metalloproteinase superfamily show that the key secondary structural elements are conserved, in spite of major variations in the sequences including insertions and deletions of functional domains. Major differences between the matrix metalloproteinases (matrixins) are clustered in two regions forming the entrance to the active site and hence may be determinants of substrate selectivity. A comparison of the structures of matrixin-inhibitor complexes shows that there are significant differences even among the closely related matrixins, not only in the peripheral regions but also in the specificity pockets; these differences offer an excellent opportunity for the design of specific inhibitors targetted to individual members.
Collapse
Affiliation(s)
- V Dhanaraj
- Department of Crystallography, Birkbeck College, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Crystal and NMR structures of helical cytokines--interleukin-4 (IL-4), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-2 (IL-2)--have been compared. Root mean square deviations in the C alpha coordinates for the conserved regions of the helices were 1-2 A between different cytokines, about twice the differences observed for independently determined crystal and solution structures of IL-4. Considerable similarity in amino acid sequence in the areas expected to interact with the receptors was detected, and the available mutagenesis data for these cytokines were correlated with structure conservation. Models of cytokine-receptor interactions were postulated for IL-4 based on its structure as well as on the published structure of human growth hormone interacting with its receptors (de Vos, A.M., Ultsch, M., & Kossiakoff, A.A., 1992, Science 255, 306-312). Patches of positively charged residues on the surfaces of helices C and D of IL-4 may be responsible for the interactions with the negatively charged residues found in the complementary parts of the IL-4 receptors.
Collapse
Affiliation(s)
- A Wlodawer
- Macromolecular Structure Laboratory, NCI-Frederick Cancer Research and Development Center, Maryland 21702
| | | | | |
Collapse
|
40
|
Abstract
The crystal structure of human recombinant interleukin-4 (IL-4) has been solved by multiple isomorphous replacement, and refined to an R factor of 0.218 at 2.25 A resolution. The molecule is a left-handed four-helix bundle with a short stretch of beta sheet. The structure bears close resemblance to other cytokines such as granulocyte-macrophage colony stimulating factor (GM-CSF). Although no sequence similarity of IL-4 to GM-CSF and other related cytokines has been previously postulated, structure-based alignment of IL-4 and GM-CSF revealed that the core of the molecules, including large parts of all four helices and extending over half of the molecule, has 30% sequence identity. This may have identified regions which are not only important to maintain structure, but could also play a role in receptor binding.
Collapse
Affiliation(s)
- A Wlodawer
- Macromolucar Structure Laboratory, NCI-Fredrick Cancer Research and Development Center, MD 21702
| | | | | | | |
Collapse
|
41
|
Abstract
Phagocytosis and lysis of C. pseudotropicalis by peripheral blood monocytes from Hodgkin's and non-Hodgkin's lymphoma were analysed. In Hodgkin's disease, there was a decrease in the phagocytic activity of blood monocytes; moreover, the candidacidal activity was significantly decreased as compared with normal controls. Although monocytes from non-Hodgkin's patients presented normal phagocytic function, the ability to kill C. pseudotropicalis was impaired. In both groups of lymphomas, the data showed that the abnormal findings were not related to treatment. These results indicate that monocytes from Hodgkin's and non-Hodgkin's lymphoma posses a deficiency in killing C. pseudotropicalis, which could be due to an intrinsic macrophage defect in the myeloperoxidase-independent mechanisms and which may be responsible for the predisposition of the se patients to candida infections.
Collapse
|
42
|
Casillas G, Simonetti C, Pavlovsky A. [Immunological studies on factor VIII in hemophilia and von Willebrand disease]. Medicina (B Aires) 1977; 37:215-22. [PMID: 302385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
43
|
Carosella ED, Braun M, Suarez A, Pavlovsky A, Bachmann AE. Rosette forming T-cells in human lymphomas: relationship with age and clinical parameters. Biomedicine 1976; 25:285-7. [PMID: 793647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Peripheral blood spontaneous rosette forming T cells (RFC) were studied in 40 Hodgkin's Disease (HD) and 20 lymphosarcoma (LS) patients, classified according to the histological type and spread of disease and to their age, treatment, clinical condition and evolution. LS patients had near normal RFC values; in HD, the lowest values of RFC corresponded to the most severe histological picture. In all patients, differences could be seen according to the spread of the disease and the clinical condition, but none in relation with treatment nor with the clinical evolution in a one year period after the test. While in controls and LS patients, RFC were higher in younger than older subjects, in HD, values were higher after 50 years of age. The usefulness of RFC test in the evaluation of lymphoma patients is discussed.
Collapse
|
44
|
Casillas G, Simonetti C, Vasquez C, Pavlovsky A. Physical, chemical and immunological studies on bovine factor VIII. Haemostasis 1976; 5:1-13. [PMID: 817987 DOI: 10.1159/000214113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Highly purified bovine factor VII prepared according to our technique and having a specific activity of 500 U/mg protein has been studied. The chemical analysis of the preparation revealed it to be composed of amino acids, lipids (8-10%) and carbohydrates (7%). The lipid moiety can be removed by chromatography. Different mechanism of inactivation of bovine factor VII and the possible molecular changes induced by the inactivating agents were studied. EDTA and EGTA provoke a weakening of the bonds linking the structural elements of the molecule, which allows for the separation of two different components of the molecule by gel filtration. Upon treatment with thrombin, the carbohydrate content of bovine factor VIII decreases without any apparent degradation of the protein moiety of the molecule. The fact that precipitating and neutralizing antisera against factor VIII were obtained, shows that the molecules modified by EDTA and thrombin still have the antigenic properties of factor VIII. The inhibitor developed by hemophiliacs transfused with human factor VIII is bound to bovine factor VIII, forming a complex reveal that it is composed of bovine factor VIII and human gamma-globulin. Bovine factor VIII in the complex retains some antigenic determinants which bind rabbit antiserum against bovine factor VIII, as shown by neutralization of the antiserum and by precipitation studies.
Collapse
|
45
|
Morgenfeld MC, Pavlovsky A, Suarez A, Somoza N, Pavlovsky S, Palau M, Barros CA. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. Cancer 1975; 36:1241-9. [PMID: 1100220 DOI: 10.1002/1097-0142(197510)36:4<1241::aid-cncr2820360409>3.0.co;2-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
One hundred ninety patients who had advanced active Hodgkin's disease, lymphosarcoma, or reticulum cell sarcoma were treated with a combination of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) given in a cyclical fashion every month. Complete remission was produced in 91 of 138 (66%) patients with Hodgkin's disease and in 39 of 52 (75%) patients with non-Hodgkin's lymphoma (lymphosarcoma and reticulum cell sarcoma). The response rate was higher in patients who completed six cycles of therapy compared to those who completed only three to five cycles: 77% vs. 45%, respectively, in Hodgkin's disease, and 85% vs. 46%, respectively, in non-Hodgkin's lymphoma. The median duration of remission was longer for Hodgkin's disease patients who completed six cycles (30 months vs. 10 months). The median duration of complete remission of non-Hodgkin's lymphoma was 14 months. The response to treatment correlated positively with survival. The median survival time start of COPP treatment for patients with Hodgkin's disease was 7 months for nonresponders, 14 months for those who attained partial remission, and more than 48 months for those who attained complete remission. For patients with non-Hodgkin's lymphoma, the median survival time from start of COPP treatment was 24 months for nonresponders and those who had partial remission, and more than 32 months for those who attained complete remission. Of complete remission responders with Hodgkin's disease, 70% are still alive 84 months after diagnosis, and 63% of the patients witn non-Hodgkin's lymphoma are still alive 48 months after diagnosis.
Collapse
|
46
|
Brieux de Salum S, Pavlovsky S, Bachmann AE, Larripa I, Caltabiano A, Pavlovsky A. A new surface adherent cell line derived from a suspension culture of human lymphoblastoid cells. Medicina (B Aires) 1975; 35:149-53. [PMID: 1134337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
47
|
Abstract
A total of 114 previously untreated patients with myeloblastic leukemia was included in a sequential therapy protocol. Daunorubicin, vincristine, and prednisone were employed for the first 3 weeks, followed by two or more 5-day courses of cytosine arabinoside and 6-mercaptopurine; there was a 5-day rest between courses. Maintenance therapy was as follows: the continuing 6-mercaptopurine and methotrexate treatment was interrupted every 30 days for sequential reinforcement courses consisting of one dose of daunorubicin and vincristine and 7 days of prednisone, or by a 5-day course of cytosine arabinoside plus 6-mercaptopurine. Of the 114 patients, 48 obtained complete remission, 14 had partial remission, 16 failed to respond, and 36 died during the course of treatment. The remission rate in children (under 16) was 57%; in adults (16-45) 54%; and in those over 45, 19%. The difference in the incidence of complete remission in patients under 45 and those over 45 was statistically significant (p less than 0.01). The median duration of complete remission was 8 months: 12 months in children and 5 months in adults. The over-all survival rate was 4 months: 13 months for patients with complete remission, 4 months for those with partial remission, and 1 month for patients who did not respond to therapy. The difference in survival of those with complete remission and all the others was significant (p less than 0.01).
Collapse
|
48
|
Sackmann Muriel F, Pavlovsky S, Peñalver JA, Hidalgo G, Cebrian Bonesana A, Eppinger-Helft M, De Macchi GH, Pavlovsky A. Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia. Cancer 1974; 34:418-26. [PMID: 4527793 DOI: 10.1002/1097-0142(197408)34:2<418::aid-cncr2820340227>3.0.co;2-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
49
|
Bachmann AE, Giraudo Conesa LC, Braun M, Garcia Ben M, Pavlovsky A. Immunológical studies in lymphoma patients IX. Detection of antimycotic antibodies. Medicina (B Aires) 1974; 34:25-8. [PMID: 4210127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
50
|
Bachmann AE, Giraudo Conesa LC, Sen L, Scornik JC, De Salum SB, Pavlovsky A. In vitro culture of human normal and lymphoma cells. Cytochemical study and uptake of labeled nucleic acid precursors. Acta Cytol 1973; 17:209-13. [PMID: 4121638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|